
    
      The study is a Phase 2, global, prospective, multi-dose, double-blind, double-dummy,
      active-control, randomized, parallel-group, multicenter study of oral zabofloxacin HCl
      (400mg) versus oral levofloxacin (500mg) in the treatment of adults with community-acquired
      pneumonia of moderate severity.
    
  